Directory
Serafin Morales Murillo

Serafin Morales Murillo

Degree: PhD

973 70 53 03
smorales.lleida.ics(ELIMINAR)@gencat.cat

ResearcherID: http://www.researcherid.com/rid/L-7216-2019

Publications

  • Aguirre, E.; Morales, S.; Llombart, A.

    Other malignancies I. breast cancer

    Other Malignancies I. Breast Cancer 235-251. .

  • Sanchez-Rovira, P.; Segui, M. A.; Llombart, A.; Aranda, E.; Anton, A.; Sanchez, A.; Lomas, M.; Jaen, A.; Fernandez, M.; Porras, I.; Dalmau, E.; Morales, S.; de la Haba-Rodriguez, J.

    Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response

    CLINICAL & TRANSLATIONAL ONCOLOGY 15 810-817. .

    [doi:10.1007/s12094-013-1006-4]

  • Aguirre E; Taberner T; Luaña A; Morales S; Llombart A

    Severe thrombocytopenia related to long-term trastuzumab exposure.

    Tumori 99 -. .

    [doi:10.1700/1248.13801]

  • Martin, Miguel; Segui, Miguel A.; Anton, Antonio; Ruiz, Amparo; Ramos, Manuel; Adrover, Encarna; Aranda, Ignacio; Rodriguez-Lescure, Alvaro; Grosse, Regina; Calvo, Lourdes; Barnadas, Agusti; Isla, Dolores; Martinez del Prado, Purificacion; Ruiz Borrego, Manuel; Zaluski, Jerzy; Arcusa, Angels; Munoz, Montserrat; Lopez Vega, Jose M.; Mel, Jose R.; Munarriz, Blanca; Llorca, Cristina; Jara, Carlos; Alba, Emilio; Florian, Jesus; Li, Junfang; Lopez Garcia-Asenjo, Jose A.; Saez, Amparo; Jose Rios, Maria; Almenar, Sergio; Peiro, Gloria; Lluch, Ana; GEICAM 9805 Investigators

    Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer.

    NEW ENGLAND JOURNAL OF MEDICINE 363 2200-2210. .

    [doi:10.1056/NEJMoa0910320]

  • Aguirre Ortega, E.; Martín Marco, A.; Canal Sotelo, J.; Morales Murillo, S.; Llombart Cussac, A.

    Dyspnea and persistent cough as first signs of distant recurrence disease

    MEDICINA DE FAMILIA-SEMERGEN 36 597-599. .

    [doi:10.1016/j.semerg.2010.02.011]

  • Rosell, Rafael; Moran, Teresa; Queralt, Cristina; Porta, Rut; Cardenal, Felipe; Camps, Carlos; Majem, Margarita; Lopez-Vivanco, Guillermo; Isla, Dolores; Provencio, Mariano; Insa, Amelia; Massuti, Bartomeu; Luis Gonzalez-Larriba, Jose; Paz-Ares, Luis; Bover, Isabel; Garcia-Campelo, Rosario; Angel Moreno, Miguel; Catot, Silvia; Rolfo, Christian; Reguart, Noemi; Palmero, Ramon; Miguel Sanchez, Jose; Bastus, Roman; Mayo, Clara; Bertran-Alamillo, Jordi; Angel Molina, Miguel; Javier Sanchez, Jose; Taron, Miquel; Spanish Lung Canc Grp

    Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer.

    NEW ENGLAND JOURNAL OF MEDICINE 361 958-38. .

    [doi:10.1056/NEJMoa0904554]

  • Baselga, J; Carbonell, X; Castaneda-Soto, NJ; Clemens, M; Green, M; Harvey, V; Morales, S; Barton, C; Ghahramani, P

    Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule

    Journal of Clinical Oncology 23 2162-2171. .

    [doi:10.1200/JCO.2005.01.014]

  • Espinosa, E; Morales, S; Borrega, P; Casas, A; Madronal, C; Machengs, I; Illarramendi, J; Lizon, J; Moreno, J; Belon, J; Janariz, J; de la Puente, M; Checa, T; Mel, JR; Baron, MG

    Docetaxel and high-dose epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer

    CANCER CHEMOTHERAPY AND PHARMACOLOGY 54 546-552. .

    [doi:10.1007/s00280-004-0830-1]

  • Morales, S; Lorenzo, A; Ramos, M; Ballesteros, P; Mendez, M; Almanza, C; Castellanos, J; Moreno-Nogueira, JA; Casal, J; Lizon, J; Oltra, A; Frau, A; Machengs, I; Galan, A; Belon, J; Llorca, C

    Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study

    CANCER CHEMOTHERAPY AND PHARMACOLOGY 53 75-81. .

    [doi:10.1007/s00280-003-0690-0]

  • Alberola, V; Camps, C; Provencio, M; Isla, D; Rosell, R; Vadell, C; Bover, I; Ruiz-Casado, A; Azagra, P; Jimenez, U; Gonzalez-Larriba, JL; Diz, P; Cardenal, F; Artal, A; Carrato, A; Morales, S; Sanchez, JJ; de las Penas, R; Felip, E; Lopez-Vivanco, G

    Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish lung cancer group phase III randomized trial

    Journal of Clinical Oncology 21 3207-3213. .

    [doi:10.1200/JCO.2003.12.038]

  • Espinosa, E; Zamora, P; Milla, A; Morales, S; Molina, R; Mira, M; Baron, MG; Oncopaz Cooperative Grp

    A phase II trial of cisplatin and vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK 24 1054-1059. .

    [doi:10.1002/hed.10172]

  • Morales, S; Salud, A; Balil, A; Mira, M; Garcia, E; Carceller, JA

    Paclitaxel (P), gemcitabine (G) and cisplatin (c) in non-resectable non-small cell lung cancer (NSCLC).

    ANNALS OF ONCOLOGY 11 527-527. .

Projects

  • Diseño y testaje de péptidos de interferencia para el tratamiento del cáncer de mama triple negativo
  • Development of Computer Application (Apps) for Information and Monitoring of Patients with Breast Cancer at the Hospital Arnau de Vilanova De Lleida
  • SELECCIÓN DE TRATAMIENTO CON QUIMIOTERAPIA NEOADYUVANTE EN PACIENTES CON CÁNCER DE MAMA EN ESTADIO PRECOZ Y CON RECEPTORES HORMONALES POSITIVOS MEDIANTE LA DETERMINACIÓN DE LA PLATAFORMA ONCOTYPE, CF DNA EN SANGRE PERIFÉRICA Y CAMBIOS DEL MARCADOR KI67 EN TEJIDO TUMORAL.
  • Cáncer de mama: utilidad pronóstica de los Perfiles de Expresión Proteica en pacientes con tumor residual viable (>1.0 cm) tras quimioterapia neoadyuvante